Clinical Evidence in FDA Drug Approvals Varies Widely

Modern Healthcare, January 22, 2014. “With new drugs, there is often an exaggeration of the benefits and underreporting of the risks,” said Diana Zuckerman, NCHR president, who has testified at several hearings on drug safety. “There’s so much emphasis on drugs being the latest, the most innovative and novel—but unfortunately this usually means it’s just new, not necessarily better.”

Read More »